Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQUOIA phase 2 placebo-controlled dose-finding study of ARO-AAT in alpha-1 antitrypsin deficiency
NL-OMON54898Phase 2Active, not recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Oct 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of fazirsiran in alpha-1 antitrypsin deficiency (AATD), sponsored by Arrowhead Pharmaceuticals. Started Oct 2020; status: active, not recruiting.
02
Drugs
fazirsiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NL-OMON54898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54898.